Clinical Scorecard: Frontline Pharma: Sarah O’Keeffe

At a Glance

Key Highlights

• FDA approval of orforglipron (Foundayo) as a once-daily oral obesity treatment.
• Innovative synthesis process for orforglipron is seven times more efficient.
• Integration of advanced data science and AI in drug development.
• Focus on sustainable manufacturing and reduced waste in drug synthesis.
• Development of patient-friendly drug delivery systems.

Guideline-Based Recommendations

Diagnosis

• Assess BMI and obesity-related comorbidities.

Management

• Consider GLP-1 receptor agonists for weight management.

Monitoring & Follow-up

• Regular follow-up on weight loss and side effects.

Risks

• Monitor for gastrointestinal side effects and potential pancreatitis.

Patient & Prescribing Data

Adults with obesity, including those with comorbid conditions.

Orforglipron can be taken without food or water restrictions.

Clinical Best Practices

• Utilize efficient synthesis methods to enhance drug development.
• Incorporate multi-dimensional chromatography in analytical processes.
• Leverage digital technologies for accelerated clinical supply.

References

• Eli Lilly